← SynDRA
ALISERTIB
SynDRA canonical compound SYN0018867 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | AURKA |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- aurora kinase inhibitor
- AURKA INHIBITOR
- Serine/threonine-protein kinase Aurora-A inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DNAJA1
- BTK
- NDUFA13
- LIMK1
- LCK
- SRC
- EPHA2
- SLK
- NTRK3
- HCK
- GNAI2
- CLK4
- PDPK1
- RET
- GABRA1
- FRK
- RAB10
- CSNK2A2
- PTK2
- FGFR1
- FER
- PRKDC
- EPHB4
- PLK4
- EGFR
- SYK
- NTRK1
- EPHA4
- ACAD10
- TNK1
- TNK2
- AURKB
- ABL1
- YES1
- MCM4
- BLK
- ABL2
- MAT2A
- PIM1
- MARK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CSK21
- GAMT
- GNMT
- HNMT
- INCENP
- IP6K1
- KAPCA
- KS6A3
- KSYK
- NNMT
- NSD2
- PNMT
- TPX2
- VGFR1
- VGFR2
Cross-references
Synonyms
- MLN-8237
- ALISERTIB (MLN8237)
- Alisertib sodium
- CHEMBL483158
- MLN-8237-004
- MLN8237
- MLN 8237
- MLN8237 (Alisertib)
- 4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid
- Alisertib [USAN]
- 4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
- T66ES73M18
- Alisertib (USAN)
- 4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid
- 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl) -5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid
- Benzoic acid, 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxy-
- Alisertib [USAN:INN]
- UNII-T66ES73M18
- MLN8237,Alisertib
- Kinome_3770
- ALISERTIB [INN]
- Alisertib; MLN8237
- Alisertib (MLN8237)
- MLN8237 - Alisertib
- ALISERTIB [WHO-DD]
- MLS006011041
- SCHEMBL855823
- GTPL7790
- DTXSID30145539
- EX-A024
- MIN8237
- CHEBI:125628
- HMS3654E08
- HMS3673I07
- HMS3743E17
- AMY24201
- BCP01823
- BDBM50277545
Look up ALISERTIB in the interactive SynDRA portal →